efficacy and safety of tacrolimus for mild/modelate flare in patients with systemic lupus erythematosus

INTERVENTION: Administration of Tacrolimus CONDITION: systemic lupus erythematosus PRIMARY OUTCOME: Time to discontinuation of treatment; Time to flare rate; Dose of prednisolone SECONDARY OUTCOME: SLE Disease Activity Index (SLEDAI); Anti‐double‐stranded DNA antibody titer; Serum complement titer INCLUSION CRITERIA: 1 Patients with diagnosed according to the American College of Rheumatology criteria of SLE 2 Patients has complicated lupus nephritis 3 Patients maintained with prednisolone less than 10 mg/day for at least 3 months before the entry. 4 Patients with mild/modelate flare during treatment with prednisolone alone or prednisolone concomitant with immunosuppressant (except for TAC or CsA)